Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Dano Novo Nordisk, Diabean Diabetes Manufacturer, Diabetes Blockbuster and Weight Treatment Manager, and Vegvi see Terry’s Vegwi when the company presents an annual report in Novo Nordisk in Bohd, Denmark, February 5, 2025.
Mads Claus Rasmussen | AFP | Gets the image
Novo nordisk On Wednesday, promising test results at the late stage for the new treatment of obesity of Kagrinitis, since the Danish pharmaceutical giant is looking for an alternative to the next generation to its blockbuster Wegovy with weight loss.
Early analysis from phase 3 Revate 1 test shows that injection of monotherapy has ever helped patients reduce weight by 11.8% on average 68 weeks compared to 2.3% for those in placebo, the company notes.
CAGRILINTIDE-It is charged with weight loss treatment, which is distinguished by existing GLP-1, such as Wegovy Novo Nordisk and Zepbound Eli Lilly. A long analogue of amilin, which works, mimicing the hormone, which with insulin in the pancreas to increase saturation.
Drug manufacturer also pointed to increased treatment profile, describing it as “well tolerated”, and the most common side effects are gastrointestinal and mostly “light and moderate”.
Novo Nordisk shares rose 1.3% to 11:15 am in London, shortly after the conclusions were released.
“In our clinical trials, Cagrilintide has provided a significant weight loss, clearly expressed compared to the approved obesity medicines, and it appears to be well tolerated,” said Martin Holst Lange, Chief Research and Executive Vice President.
“We are excited that this data, the first data phase 3 of the next generation therapy, shows a promise, and we look forward to further study of the Cagrilintide potential in the 3rd phase recovery program,” Langge added.
Novo Nordisk seeks to treat the next -generation obesity after escaping the success of the Azerbic diabetes and the treatment of the vega obesity recently has been under pressure restrictions and enhance competition from the copy consisting of drugs.
Drug manufacturers are also looking for alternative treatments for patients seeking to stay in the long term GLP-1. Roche and Zealand Pharma also develop treatment with an analogue of amiline obesity, known as perelintide.
Investors were before disappointed By late stage of results for Cagrisema, combined therapy that combines semaglutide, active in Wegovy as well as Cagrilintide.
However, Soren Lontoft, Pharma Equity analyst at Sydbank, said CNBC that the side effect profile was perhaps the most promising aspects of new treatment.
“The side effects profile for Cagrilintide is of greater interest than weight loss. The more favorable side effects profile (low stopping) than Wegovy and Zepbound is what I look for,” Lontoft said on Tuesday.
Sub-analysis test results presented in the European Association of Diabetes Congress in Vienna, Austria, evaluated adult patients with obesity or overweight, as well as a associated weight without diabetes.
The highlighted test at the stage 3 – in which the study of the efficiency and safety of the drug in patients with obesity or overweight, but without associated comorbidities – is scheduled to start in the late 2025.
